Earnings
Natera Raises Sales Outlook By $140 Million — And Increases Research And Marketing Budgets
Oncology test volume grew 60.9% from a year earlier, while the quarterly net loss narrowed and annual cash flow is still forecast positive.
Natera (NTRA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Oncology test volume grew 60.9% from a year earlier, while the quarterly net loss narrowed and annual cash flow is still forecast positive.
Markets
Natera lifted its revenue outlook and appointed Solomon Moshkevich CEO, with a plan to double sales.
Earnings
The new CEO says doubling revenue in three years needs "no big miracles," with early cancer screening barely counted in the plan.
Earnings
The third-quarter filing swaps the AI and billing-efficiency story for collections estimates catching up with cash, alongside a CEO change.
SEC Filings
FMR and chairman Abigail Johnson reported 13.7 million Natera shares, a position that sits under a certification of no control intent.